Recently, the NIA-AA criteria included different Nuclear Medicine neuroimaging procedures in the AT(N) framework of AD diagnosis, and three general groups of biomarkers, based on the nature of the pathologic AD process that each expresses, have been identified; A stands for Amyloid aggregates, T for Tau presence, and N for neurodegenerative process [6]. This evidence concerns the gene MAPT and Alzheimer disease.